These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20665754)

  • 1. Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice.
    Prow TW; Chen X; Prow NA; Fernando GJ; Tan CS; Raphael AP; Chang D; Ruutu MP; Jenkins DW; Pyke A; Crichton ML; Raphaelli K; Goh LY; Frazer IH; Roberts MS; Gardner J; Khromykh AA; Suhrbier A; Hall RA; Kendall MA
    Small; 2010 Aug; 6(16):1776-84. PubMed ID: 20665754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective immunization of the endangered California condors (Gymnogyps californianus) protects this species from lethal West Nile virus infection.
    Chang GJ; Davis BS; Stringfield C; Lutz C
    Vaccine; 2007 Mar; 25(12):2325-30. PubMed ID: 17224209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse.
    El Garch H; Minke JM; Rehder J; Richard S; Edlund Toulemonde C; Dinic S; Andreoni C; Audonnet JC; Nordgren R; Juillard V
    Vet Immunol Immunopathol; 2008 Jun; 123(3-4):230-9. PubMed ID: 18372050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.
    McDonald WF; Huleatt JW; Foellmer HG; Hewitt D; Tang J; Desai P; Price A; Jacobs A; Takahashi VN; Huang Y; Nakaar V; Alexopoulou L; Fikrig E; Powell TJ
    J Infect Dis; 2007 Jun; 195(11):1607-17. PubMed ID: 17471430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of West Nile virus infectious DNA and its noninfectious derivatives.
    Seregin A; Nistler R; Borisevich V; Yamshchikov G; Chaporgina E; Kwok CW; Yamshchikov V
    Virology; 2006 Dec 5-20; 356(1-2):115-25. PubMed ID: 16935318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis.
    Dean HJ; Fuller D; Osorio JE
    Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):373-88. PubMed ID: 12818623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development.
    Throsby M; Ter Meulen J; Geuijen C; Goudsmit J; de Kruif J
    Expert Rev Vaccines; 2007 Apr; 6(2):183-91. PubMed ID: 17408368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of West Nile virus live vaccine candidates attenuated by capsid deletion mutations.
    Schlick P; Kofler RM; Schittl B; Taucher C; Nagy E; Meinke A; Mandl CW
    Vaccine; 2010 Aug; 28(36):5903-9. PubMed ID: 20600500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of an attenuated West Nile virus vaccine, live Flavivirus chimera in horses.
    Long MT; Gibbs EP; Mellencamp MW; Zhang S; Barnett DC; Seino KK; Beachboard SE; Humphrey PP
    Equine Vet J; 2007 Nov; 39(6):486-90. PubMed ID: 18065304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine.
    Samina I; Havenga M; Koudstaal W; Khinich Y; Koldijk M; Malkinson M; Simanov M; Perl S; Gijsbers L; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2007 Nov; 25(49):8338-45. PubMed ID: 17977629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.
    Long MT; Gibbs EP; Mellencamp MW; Bowen RA; Seino KK; Zhang S; Beachboard SE; Humphrey PP
    Equine Vet J; 2007 Nov; 39(6):491-7. PubMed ID: 18065305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.
    Desprès P; Combredet C; Frenkiel MP; Lorin C; Brahic M; Tangy F
    J Infect Dis; 2005 Jan; 191(2):207-14. PubMed ID: 15609230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999).
    Yang JS; Kim JJ; Hwang D; Choo AY; Dang K; Maguire H; Kudchodkar S; Ramanathan MP; Weiner DB
    J Infect Dis; 2001 Oct; 184(7):809-16. PubMed ID: 11550123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine.
    Lim CK; Takasaki T; Kotaki A; Kurane I
    Virology; 2008 Apr; 374(1):60-70. PubMed ID: 18221765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective cutaneous vaccination using an inactivated chikungunya virus vaccine delivered by Foroderm.
    Rudd PA; Raphael AP; Yamada M; Nufer KL; Gardner J; Le TT; Prow NA; Dang N; Schroder WA; Prow TW; Suhrbier A
    Vaccine; 2015 Sep; 33(39):5172-80. PubMed ID: 26296498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ChimeriVax-West Nile vaccine.
    Hall RA; Khromykh AA
    Curr Opin Mol Ther; 2007 Oct; 9(5):498-504. PubMed ID: 17932814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A DNA-based West Nile virus replicon elicits humoral and cellular immune responses in mice.
    Cao F; Li XF; Yu XD; Deng YQ; Jiang T; Zhu QY; Qin ED; Qin CF
    J Virol Methods; 2011 Dec; 178(1-2):87-93. PubMed ID: 21893098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays.
    Chen X; Kask AS; Crichton ML; McNeilly C; Yukiko S; Dong L; Marshak JO; Jarrahian C; Fernando GJ; Chen D; Koelle DM; Kendall MA
    J Control Release; 2010 Dec; 148(3):327-33. PubMed ID: 20850487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system.
    Widman DG; Ishikawa T; Fayzulin R; Bourne N; Mason PW
    Vaccine; 2008 May; 26(22):2762-71. PubMed ID: 18423946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate.
    Ohtaki N; Takahashi H; Kaneko K; Gomi Y; Ishikawa T; Higashi Y; Kurata T; Sata T; Kojima A
    Vaccine; 2010 Sep; 28(40):6588-96. PubMed ID: 20678586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.